Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Recommendation of “Buy” from Brokerages
Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) has been assigned a consensus rating of “Buy” from the eight research firms that are presently covering the company, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have issued ratings on the stock […]
More Stories
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $53.00
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target reduced by equities researchers at Royal Bank of Canada...
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $53.00
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target reduced by equities researchers at Royal Bank of Canada...
Atmos Energy Co. (NYSE:ATO) Given Consensus Rating of “Moderate Buy” by Analysts
Shares of Atmos Energy Co. (NYSE:ATO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the...
Atmos Energy Co. (NYSE:ATO) Given Consensus Rating of “Moderate Buy” by Analysts
Shares of Atmos Energy Co. (NYSE:ATO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the...
Analysts Set Tidewater Inc. (NYSE:TDW) Price Target at $111.25
Tidewater Inc. (NYSE:TDW – Get Free Report) has received an average rating of “Buy” from the five ratings firms that...
Analysts Set Tidewater Inc. (NYSE:TDW) Price Target at $111.25
Tidewater Inc. (NYSE:TDW – Get Free Report) has received an average rating of “Buy” from the five ratings firms that...